Elevance Health Inc. (ELV) reported $201.83B of revenue for the twelve months ended Sep 30, 2026. That is up 3.6% from the year before. Revenue for fiscal 2025 was $199.13B.

Yes. Elevance Health Inc. earned $5.13B in net income for the twelve months ended Sep 30, 2026, a net margin of 2.5%.

How much cash and debt does ELV have?

Elevance Health Inc. reported $10.35B in cash and cash equivalents and $30.76B of debt on its most recent balance sheet in SEC filings.

How fast is ELV revenue growing?

Elevance Health Inc.'s revenue changed +12.5% in fiscal 2025, to $199.13B. Its compound annual growth rate was +10.3% over 5 years and +9.7% over 10 years.

What is ELV free cash flow?

Elevance Health Inc. generated $6.51B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $7.60B less capital expenditures.

What is ELV earnings per share?

Diluted earnings per share were $23.54 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.

When did ELV last report financial results?

The latest statements here come from Elevance Health Inc.'s 10-Q filed on Oct 21, 2026, covering the period ended Sep 30, 2026.

Where does this ELV financial data come from?

Quantisnow builds these statements from the structured XBRL data Elevance Health Inc. files with the SEC. It is provided for information only and is not investment advice.

Financials · ELV

Elevance Health Inc. (ELV) financials

For the twelve months ended Sep 30, 2026, Elevance Health Inc. reported $201.83B of revenue and $5.13B of net income.

Revenue, TTM: $201.83B
Revenue growth, YoY: +3.6%
Net income, TTM: $5.13B
Net income growth, YoY: -7.4%
Net margin: 2.5%
Free cash flow, TTM: $6.51B
EPS, diluted, TTM: $23.54
EPS growth, YoY: -4.0%
Cash: $10.35B
Total debt: $30.76B
P/E: 17.94
P/S: 0.46
Market cap: $91.96B

Annual revenue$199.13B

FY2016FY2025

Annual net income$5.66B

FY2016FY2025

Annual free cash flow$3.17B

FY2016FY2025

ELV revenue and earnings growth

ELV revenueQ3 2026$51.43B

Quarter YoY: +1.4%
QoQ: +1.9%
FY YoY: +12.5%
5Y CAGR: +10.3%
10Y CAGR: +9.7%

ELV revenue was $51.43B in fiscal Q3 2026 (ended Sep 30, 2026), up 1.4% from a year earlier and up 1.9% from the prior quarter. For the full fiscal 2025 it was $199.13B, up 12.5% from fiscal 2024. Compound annual growth was +10.3% over 5 years and +9.7% over 10 years. It rose in each of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

ELV net incomeQ3 2026$1.36B

Quarter YoY: +14.8%
QoQ: -6.1%
FY YoY: -5.3%
5Y CAGR: +4.4%
10Y CAGR: +8.3%

ELV net income was $1.36B in fiscal Q3 2026 (ended Sep 30, 2026), up 14.8% from a year earlier and down 6.1% from the prior quarter. For the full fiscal 2025 it was $5.66B, down 5.3% from fiscal 2024. Compound annual growth was +4.4% over 5 years and +8.3% over 10 years. It rose in 4 of the last 10 fiscal years.

ELV EPSQ3 2026$6.27

Quarter YoY: +17.9%
QoQ: -6.6%
FY YoY: -1.8%
5Y CAGR: +7.0%
10Y CAGR: +10.4%

ELV diluted EPS was $6.27 in fiscal Q3 2026 (ended Sep 30, 2026), up 17.9% from a year earlier and down 6.6% from the prior quarter. For the full fiscal 2025 it was $25.21, down 1.8% from fiscal 2024. Compound annual growth was +7.0% over 5 years and +10.4% over 10 years.

ELV free cash flowQ3 2026$1.00B

Quarter YoY: +29.0%
QoQ: -38.5%
FY YoY: -30.3%
5Y CAGR: -20.0%
10Y CAGR: -1.2%

ELV free cash flow was $1.00B in fiscal Q3 2026 (ended Sep 30, 2026), up 29.0% from a year earlier and down 38.5% from the prior quarter. For the full fiscal 2025 it was $3.17B, down 30.3% from fiscal 2024. Compound annual growth was -20.0% over 5 years and -1.2% over 10 years. It rose in 3 of the last 10 fiscal years.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue	$199.13B	$177.01B	$171.34B	$156.59B	$138.64B	$121.87B	$104.21B	$92.11B	$90.04B	$84.86B
Cost of revenue	$21.18B	$19.75B	$17.29B	$13.04B	$10.89B	$8.95B	$1.99B	$0	$0	-
Selling, general and admin	$20.98B	$20.02B	$20.09B	$17.70B	$15.92B	$17.45B	$13.36B	$14.02B	$12.65B	$12.56B
Operating income	$7.20B	$7.86B	$8.50B	$8.28B	$7.56B	$6.36B	$6.00B	$5.43B	$4.17B	$4.80B
Interest expense	$1.40B	$1.19B	$1.03B	$851.00M	$798.00M	$784.00M	$746.00M	$753.00M	$739.00M	$723.00M
Pre-tax income	$6.71B	$7.90B	$7.71B	$7.60B	$8.00B	$6.24B	$5.99B	$5.07B	$3.96B	$4.55B
Income tax	$1.05B	$1.93B	$1.72B	$1.71B	$1.85B	$1.67B	$1.18B	$1.32B	$121.00M	$2.08B
Net income	$5.66B	$5.98B	$5.99B	$5.89B	$6.16B	$4.57B	$4.81B	$3.75B	$3.84B	$2.47B
EPS, basic	$25.28	$25.81	$25.38	$24.56	$25.26	$18.23	$18.81	$14.53	$14.70	$9.39
EPS, diluted	$25.21	$25.68	$25.22	$24.28	$24.95	$17.98	$18.47	$14.19	$14.35	$9.21
Diluted shares	224.6M	232.9M	237.4M	242.8M	246.8M	254.3M	260.3M	264.2M	267.8M	268.1M

Balance sheet

Balance sheet
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Cash and equivalents	$9.49B	$8.29B	$6.53B	$7.39B	$4.88B	$5.74B	$4.94B	$3.93B	$3.61B	$4.08B
Current assets	$63.00B	$58.94B	$60.03B	$55.62B	$51.12B	$45.75B	$39.03B	$34.32B	$36.26B	$34.31B
Goodwill	$28.34B	$28.28B	$25.32B	$24.38B	$24.23B	$21.69B	$20.50B	$20.50B	$19.23B	$17.56B
Total assets	$121.49B	$116.89B	$108.93B	$102.75B	$97.46B	$86.61B	$77.45B	$71.57B	$70.54B	$65.08B
Current liabilities	$41.03B	$40.58B	$41.79B	$39.70B	$34.88B	$29.45B	$23.53B	$21.96B	$23.36B	$21.29B
Short-term debt	$1.10B	$1.65B	$1.65B	$1.50B	$1.60B	$700.00M	$1.60B	$849.00M	$1.27B	$928.40M
Long-term debt	$30.80B	$29.22B	$23.25B	$22.35B	$21.16B	$19.34B	$17.79B	$17.22B	$17.38B	$14.36B
Total debt	$31.90B	$30.87B	$24.89B	$23.85B	$22.76B	$20.04B	$19.39B	$18.07B	$18.66B	$15.29B
Total liabilities	$77.47B	$75.46B	$69.52B	$66.42B	$61.29B	$53.42B	$45.73B	$43.03B	$44.04B	$39.98B
Shareholders' equity	$43.88B	$41.43B	$39.41B	$36.33B	$36.14B	$33.19B	$31.69B	$28.57B	$26.50B	$25.10B

Cash flow

Cash flow
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Operating cash flow	$4.29B	$5.81B	$8.06B	$8.40B	$8.36B	$10.69B	$6.06B	$3.83B	$4.18B	$3.27B
Capital expenditures	$1.12B	$1.26B	$1.30B	$1.15B	$1.09B	$1.02B	$1.08B	$1.21B	$791.00M	$584.00M
Free cash flow	$3.17B	$4.55B	$6.76B	$7.25B	$7.28B	$9.67B	$4.98B	$2.62B	$3.39B	$2.69B
Investing cash flow	-$1.34B	-$5.17B	-$5.57B	-$4.56B	-$9.64B	-$7.32B	-$2.79B	-$1.26B	-$5.08B	-$514.00M
Financing cash flow	-$1.74B	$1.19B	-$3.35B	-$1.32B	$423.00M	-$2.57B	-$2.27B	-$2.24B	$427.00M	-$799.00M
Dividends paid	$1.53B	$1.51B	$1.40B	$1.23B	$1.10B	$954.00M	$818.00M	$776.00M	$705.00M	$684.00M
Share repurchases	$2.60B	$2.90B	$2.68B	$2.32B	$1.90B	$2.70B	$1.70B	$1.69B	$2.00B	$0
Stock-based compensation	$276.00M	$191.00M	$289.00M	$264.00M	$255.00M	$283.00M	$294.00M	$226.00M	$170.00M	$165.00M
Depreciation and amortization	$1.55B	$1.39B	$1.75B	$1.68B	$1.30B	$1.15B	$1.13B	$1.13B	-	-

Key ratios

Key ratios
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue growth, YoY	12.5%	3.3%	9.4%	13.0%	13.8%	16.9%	13.1%	2.3%	6.1%	7.2%
Net income growth, YoY	-5.3%	-0.1%	1.6%	-4.3%	34.7%	-4.9%	28.2%	-2.4%	55.6%	-3.5%
EPS growth, YoY	-1.8%	1.8%	3.9%	-2.7%	38.8%	-2.7%	30.2%	-1.1%	55.8%	-1.8%
Operating margin	3.6%	4.4%	5.0%	5.3%	5.5%	5.2%	5.8%	5.9%	4.6%	5.7%
Net margin	2.8%	3.4%	3.5%	3.8%	4.4%	3.8%	4.6%	4.1%	4.3%	2.9%
Free cash flow margin	1.6%	2.6%	3.9%	4.6%	5.2%	7.9%	4.8%	2.8%	3.8%	3.2%
Return on equity	12.9%	14.4%	15.2%	16.2%	17.0%	13.8%	15.2%	13.1%	14.5%	9.8%
Return on assets	4.7%	5.1%	5.5%	5.7%	6.3%	5.3%	6.2%	5.2%	5.4%	3.8%
Current ratio	1.54	1.45	1.44	1.40	1.47	1.55	1.66	1.56	1.55	1.61
Debt to equity	0.73	0.75	0.63	0.66	0.63	0.60	0.61	0.63	0.70	0.61

Income statement

Income statement
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue	$51.43B	$50.47B	$50.18B	$49.75B	$50.71B	$49.78B	$48.89B	$45.44B	$45.11B	$43.89B	$42.58B	$42.65B
Cost of revenue	$5.64B	$5.49B	$5.46B	$5.52B	$5.38B	$5.29B	$4.98B	$6.01B	$5.09B	$4.82B	$3.83B	$4.84B
Selling, general and admin	$5.75B	$5.55B	$6.33B	$5.42B	$5.27B	$5.00B	$5.30B	$4.80B	$5.27B	$5.07B	$4.89B	$5.00B
Operating income	$1.27B	$1.76B	$2.09B	$309.00M	$1.29B	$2.42B	$3.17B	$673.00M	$1.41B	$2.77B	$3.02B	$1.28B
Interest expense	$358.00M	$364.00M	$357.00M	$366.00M	$351.00M	$341.00M	$344.00M	$340.00M	$300.00M	$280.00M	$265.00M	$259.00M
Pre-tax income	$1.79B	$1.94B	$2.30B	$215.00M	$1.41B	$2.29B	$2.80B	$606.00M	$1.37B	$2.99B	$2.94B	$1.00B
Income tax	$451.00M	$483.00M	$544.00M	-$331.00M	$219.00M	$548.00M	$613.00M	$193.00M	$365.00M	$685.00M	$690.00M	$170.00M
Net income	$1.36B	$1.45B	$1.76B	$547.00M	$1.19B	$1.74B	$2.18B	$418.00M	$1.02B	$2.30B	$2.25B	$856.00M
EPS, basic	$6.30	$6.74	$8.03	$2.58	$5.32	$7.74	$9.64	$1.87	$4.38	$9.91	$9.65	$3.70
EPS, diluted	$6.27	$6.71	$8.00	$2.56	$5.32	$7.72	$9.61	$1.88	$4.36	$9.85	$9.59	$3.68
Diluted shares	217.6M	217.9M	220.4M	-	223.7M	225.8M	227.2M	-	233.1M	233.4M	234.2M	-

Balance sheet

Balance sheet
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Cash and equivalents	$10.35B	$10.23B	$9.66B	$9.49B	$8.71B	$8.56B	$7.50B	$8.29B	$7.87B	$6.50B	$6.23B	$6.53B
Current assets	$68.52B	$67.18B	$67.03B	$63.00B	$63.78B	$63.32B	$61.12B	$58.94B	$62.85B	$62.27B	$60.95B	$60.03B
Goodwill	$28.34B	$28.34B	$28.34B	$28.34B	$28.45B	$28.37B	$28.42B	$28.28B	$25.97B	$25.96B	$25.95B	$25.32B
Total assets	$127.80B	$126.44B	$125.83B	$121.49B	$122.75B	$121.94B	$119.72B	$116.89B	$116.53B	$112.99B	$111.89B	$108.93B
Current liabilities	$46.66B	$44.25B	$45.31B	$41.03B	$40.88B	$43.83B	$42.70B	$40.58B	$42.03B	$41.81B	$44.33B	$41.79B
Short-term debt	$375.00M	$375.00M	$350.00M	$1.10B	$749.00M	$1.65B	$1.64B	$1.65B	$2.10B	$2.90B	$2.90B	$1.65B
Long-term debt	$30.38B	$30.67B	$30.77B	$30.80B	$31.17B	$28.18B	$28.11B	$29.22B	$24.69B	$24.56B	$21.98B	$23.25B
Total debt	$30.76B	$31.04B	$31.12B	$31.90B	$31.92B	$29.83B	$29.75B	$30.87B	$26.79B	$27.46B	$24.88B	$24.89B
Total liabilities	$83.01B	$81.42B	$81.78B	$77.47B	$78.67B	$78.09B	$77.10B	$75.46B	$72.65B	$70.69B	$71.18B	$69.52B
Shareholders' equity	$44.68B	$45.02B	$44.04B	$43.88B	$44.08B	$43.85B	$42.62B	$41.43B	$43.88B	$42.30B	$40.71B	$39.41B

Cash flow

Cash flow
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Operating cash flow	$1.27B	$1.91B	$4.33B	$84.00M	$1.14B	$2.05B	$1.02B	$706.00M	$2.68B	$447.00M	$1.98B	-$2.97B
Capital expenditures	$267.00M	$287.00M	$235.00M	$293.00M	$360.00M	$267.00M	$196.00M	$322.00M	$332.00M	$323.00M	$279.00M	$326.00M
Free cash flow	$1.00B	$1.63B	$4.10B	-$209.00M	$775.00M	$1.79B	$821.00M	$384.00M	$2.35B	$124.00M	$1.70B	-$3.30B
Investing cash flow	-$1.99B	$159.00M	-$1.64B	$464.00M	-$1.22B	-$687.00M	$103.00M	-$1.64B	-$401.00M	-$818.00M	-$2.31B	-$1.03B
Financing cash flow	$838.00M	-$1.49B	-$2.52B	$236.00M	$243.00M	-$308.00M	-$1.91B	$1.41B	-$915.00M	$668.00M	$32.00M	-$394.00M
Dividends paid	$373.00M	$373.00M	$376.00M	$377.00M	$381.00M	$385.00M	$386.00M	$373.00M	$386.00M	$378.00M	$379.00M	$346.00M
Share repurchases	$330.00M	$234.00M	$1.12B	$471.00M	$876.00M	$378.00M	$880.00M	$1.81B	$60.00M	$463.00M	$566.00M	$928.00M
Stock-based compensation	$80.00M	$75.00M	$55.00M	$30.00M	$84.00M	$81.00M	$81.00M	-$29.00M	$66.00M	$92.00M	$62.00M	$72.00M
Depreciation and amortization	$363.00M	$366.00M	$354.00M	$406.00M	$387.00M	$380.00M	$373.00M	$398.00M	$231.00M	$0	$331.00M	$1.09B

Key ratios

Key ratios
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue growth, YoY	1.4%	1.4%	2.6%	9.5%	12.4%	13.4%	14.8%	6.6%	5.3%	0.5%	1.0%	6.8%
Net income growth, YoY	14.8%	-16.6%	-19.4%	30.9%	17.0%	-24.2%	-2.9%	-51.2%	-21.2%	24.0%	12.2%	-1.0%
EPS growth, YoY	17.9%	-13.1%	-16.8%	36.2%	22.0%	-21.6%	0.2%	-48.9%	-20.0%	26.4%	15.5%	1.9%
Operating margin	2.5%	3.5%	4.2%	0.6%	2.6%	4.9%	6.5%	1.5%	3.1%	6.3%	7.1%	3.0%
Net margin	2.7%	2.9%	3.5%	1.1%	2.3%	3.5%	4.5%	0.9%	2.3%	5.2%	5.3%	2.0%
Free cash flow margin	1.9%	3.2%	8.2%	-0.4%	1.5%	3.6%	1.7%	0.8%	5.2%	0.3%	4.0%	-7.7%
Current ratio	1.47	1.52	1.48	1.54	1.56	1.44	1.43	1.45	1.50	1.49	1.37	1.44
Debt to equity	0.69	0.69	0.71	0.73	0.72	0.68	0.70	0.75	0.61	0.65	0.61	0.63

Source: XBRL data Elevance Health Inc. files with the SEC, latest filing dated Oct 21, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ELV peers

Company	Revenue	Growth	Net income	Net margin	Market cap
ELV	$201.83B	+3.6%	$5.13B	2.5%	$91.96B
UNHUnitedHealth Group Incorporated	$449.66B	+3.3%	$15.88B	3.5%	$353.17B
CIThe Cigna Group	$286.32B	+6.8%	$5.99B	2.1%	$77.58B
HUMHumana Inc.	$154.19B	+22.0%	$1.25B	0.8%	$52.08B
NTRANatera Inc.	$2.91B	+37.4%	-$164.71M	-5.7%	$44.78B
CNCCentene Corporation	$203.90B	+9.7%	$1.46B	0.7%	$34.53B
ILMNIllumina Inc.	$4.54B	+5.8%	$895.00M	19.7%	$32.22B
LHLabcorp Holdings Inc.	$14.59B	+6.0%	$1.00B	6.9%	$29.77B
DGXQuest Diagnostics Incorporated	$11.84B	+9.1%	$1.13B	9.5%	$28.12B

ELV FAQ

8 questions

What is ELV revenue?
Elevance Health Inc. (ELV) reported $201.83B of revenue for the twelve months ended Sep 30, 2026. That is up 3.6% from the year before. Revenue for fiscal 2025 was $199.13B.
Is ELV profitable?
Yes. Elevance Health Inc. earned $5.13B in net income for the twelve months ended Sep 30, 2026, a net margin of 2.5%.
How much cash and debt does ELV have?
Elevance Health Inc. reported $10.35B in cash and cash equivalents and $30.76B of debt on its most recent balance sheet in SEC filings.
How fast is ELV revenue growing?
Elevance Health Inc.'s revenue changed +12.5% in fiscal 2025, to $199.13B. Its compound annual growth rate was +10.3% over 5 years and +9.7% over 10 years.
What is ELV free cash flow?
Elevance Health Inc. generated $6.51B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $7.60B less capital expenditures.
What is ELV earnings per share?
Diluted earnings per share were $23.54 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
When did ELV last report financial results?
The latest statements here come from Elevance Health Inc.'s 10-Q filed on Oct 21, 2026, covering the period ended Sep 30, 2026.
Where does this ELV financial data come from?
Quantisnow builds these statements from the structured XBRL data Elevance Health Inc. files with the SEC. It is provided for information only and is not investment advice.